Pfizer, Anthropic and longevity scientists position AI as healthcare's core infrastructure, accelerating drug design and care ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement ...

NEW YORK, June 24 /PRNewswire/ — Underscoring its commitment to scientific advancement, Pfizer Inc will launch Think Science Now, a science awareness program to promote exceptional researchers who ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The Pfizer flu vaccine uses the same type of messenger RNA science that was used in the ...

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

Pharmaceutical companies are keen to have a stake in the personalized medicine market, viewed as a growing trend in the future of healthcare and a significant source of life science innovation. As ...

Pfizer Inc. has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders. Despite skepticism over Pfizer's recent acquisitions, Metsera's ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.